

This week in techniques

| Approach | Summary | Licensing status | Publication and contact information |
|--|---|--|---|
| Drug platforms | | | |
| Salmonella-infected tumor cells for dendritic cell (DC)-based tumor vaccines | <p>Salmonella-infected tumor cells may be useful for boosting the efficacy of DCs used in cancer vaccines. In a mouse model of melanoma, DCs primed <i>ex vivo</i> with Salmonella-infected melanoma cells led to less tumor growth than DCs primed <i>ex vivo</i> with uninfected melanoma cells. Ongoing work includes testing the effect of Salmonella infection on human tumor cells.</p> <p>Provenge sipuleucel-T, an autologous cellular immunotherapy from Dendreon Corp., is marketed to treat hormone refractory prostate cancer. At least eight other companies have DC-targeted cancer vaccines in Phase I/II and preclinical development.</p> <p>SciBX 3(33); doi:10.1038/scibx.2010.1028 Published online Aug. 26, 2010</p> | <p>Patent application filed covering human treatment; available for licensing Contact: Daniela Bellomo, European Institute of Oncology, Milan, Italy e-mail: daniela.bellomo@ifom-ieo-campus.it</p> | <p>Saccheri, F. <i>et al. Sci. Transl. Med.</i>; published online July 11, 2010; doi:10.1126/scitranslmed.3000739 Contact: Maria Rescigno, European Institute of Oncology, Milan, Italy e-mail: maria.rescigno@ifom-ieo-campus.it</p> |